Novi GLP-1 2026: Pricing From $133, Cancellation Terms Most Guides Skip, and What the FDA Compounding Deadline Means Before You Enroll

SHERIDAN, Wyo., May 7, 2026 (Newswire.com) - Advertorial Disclosure: This is sponsored advertising content produced by an independent publisher in connection with a marketing arrangement. It is not independent medical advice, does not guarantee eligibility, prescriptions, pricing, availability, or results, and is not a substitute for speaking with a licensed healthcare professional. This content contains affiliate links. If a purchase is made through links in this article, a commission may be earned at no additional cost to the reader.

Medical Notice: GLP-1 receptor agonists are prescription medications with documented risks, side effects, contraindications, and eligibility requirements. Always consult a qualified, licensed healthcare professional before starting, stopping, or changing any prescription treatment program.

Novi GLP-1 Program: Pricing, Cancellation Terms, and Why the June 2026 FDA Deadline Changes What to Ask Before You Enroll

Last verified: May 2026. This guide reflects Novi's current published program terms, the FDA's April 30, 2026 proposed rule on compounded GLP-1 medications, and the June 29, 2026 public comment deadline. Pricing and regulatory conditions are subject to change. Verify directly with Novi before enrolling.

If you're researching Novi's GLP-1 program in May or June 2026, you're doing it at an unusually important moment - and most of the guides you've already read haven't told you why.

On April 30, 2026, the FDA proposed formally excluding compounded semaglutide and tirzepatide from the rules that govern large-scale pharmacy compounding. The public comment period on that proposal closes June 29, 2026. That date doesn't automatically shut down Novi's program. But it does mean anyone making a multi-month financial commitment right now is doing so against a regulatory backdrop that will look different by late summer - and every legitimate guide about any compounded GLP-1 program written in 2026 should say so plainly.

This one does.

You don't need to be convinced that GLP-1 medications work. You've already seen the data and done enough reading to know this class of drugs has genuinely changed what's possible for weight management. What you need is specific, verified information about Novi as a program right now - whether it's legitimate, what the fine print actually says, how the pricing holds up at checkout, and what the regulatory picture means before you commit.

Every section of this guide is built on verified information from Novi's official website and published Terms of Service, current FDA guidance, and sourced market data. Where information is limited or uncertain, it's named clearly. Where the fine print differs from the marketing language, both versions appear side by side - because giving you everything you need to make the call yourself is the whole point.

One thing upfront: this content contains affiliate links. A commission may be earned if you enroll through the links here, at no additional cost to you. That relationship doesn't change what's written. The cancellation conflict, the regulatory context, and the pricing discrepancies all appear in full - because that's what makes this guide worth your time.

View the current Novi offer (official Novi page)

What Is Novi and Who Operates It?

Novi is a telehealth weight-loss platform. According to Novi's published materials, the company is operated by Novi International LLC, a registered entity with a mailing address of 30 N Gould St Ste R, Sheridan, Wyoming 82801. According to the company's website, more than 100,000 patients have started a GLP-1 journey through the platform.

Before evaluating whether Novi is right for you, it's worth understanding how the program is actually structured - because three separate entities are involved, and understanding which one does what matters.

Novi International LLC is the technology platform. It handles intake, enrollment, and coordination between the other parties. According to Novi's own Terms of Service, the company does not provide medical advice or medical care.

Licensed clinicians - the physicians and nurse practitioners named on Novi's website with their board certifications disclosed - are independent providers who evaluate your health profile and determine whether a prescription is appropriate. The prescription decision belongs to them, not to Novi.

Licensed compounding pharmacies receive the prescription, prepare the medication, and ship it. According to the company's materials, all medications are sourced from licensed U.S. pharmacies.

This structure defines each party's accountability - and it's the structure regulators look at when evaluating whether a telehealth GLP-1 program is operating within legal boundaries.

Novi carries a LegitScript certification - a third-party verification credential that is commonly used by major advertising platforms, payment processors, and online healthcare ecosystems as a verification signal for certain healthcare-related businesses. It's a meaningful indicator that the platform has been reviewed against defined standards, though it doesn't guarantee clinical outcomes or predict future regulatory changes.

What Novi Offers: The Two Medication Programs

According to Novi's source materials, the company markets two compounded prescription GLP-1 programs to eligible patients. Here's what the company describes, alongside the regulatory context you need to evaluate each accurately.

Compounded Semaglutide Program

According to Novi's offer-page source material reviewed for this guide, the brand advertises this as its most affordable option. Novi's offer-page material describes a promotional price starting from $133 per month, reflecting a stated $200 discount. The company's materials describe this program as involving the same active ingredient associated with branded medications Ozempic® and Wegovy®.

What you need to understand about that description: Compounded semaglutide is not an FDA-approved finished drug product. It is not a generic equivalent of Ozempic® or Wegovy®. It has not been reviewed by the FDA for safety, effectiveness, or quality before marketing. The FDA has specifically warned that direct-to-consumer marketing cannot imply equivalence with FDA-approved drugs - including through references to "the same active ingredient." This regulatory position applies to every compounded semaglutide program in the market, not to Novi specifically.

The FDA has also warned patients and providers about dosing errors associated with compounded injectable semaglutide products, including errors involving measurement units and self-administration that have required hospitalization. Use compounded GLP-1 medications only as prescribed and confirm dosing instructions directly with the prescribing clinician or dispensing pharmacy before administering.

Compounded Tirzepatide Program

According to Novi's offer-page source material, the brand describes this as its most popular option. Promotional pricing is listed from $166 per month under the same $200 promotional structure. The company's materials describe this program as involving the same active ingredient associated with Mounjaro^® and Zepbound^®.

The same regulatory context applies: compounded tirzepatide is not an FDA-approved finished drug product, is not a generic equivalent of those branded medications, and has not been reviewed by the FDA before marketing.

A note on pricing before you go further: Novi's offer pages, standard homepage, and checkout flow may each display different numbers. Novi's offer-page material advertised semaglutide from $133 and tirzepatide from $166, while other Novi pages and pricing structures may show different figures. Consumers should rely on the final checkout screen - and written confirmation from Novi - before enrolling. The affiliate link in this guide routes to a promotional offer.

Clinical context on this medication class (for informational purposes only): In clinical trials involving FDA-approved branded medications, both semaglutide and tirzepatide have produced meaningful average weight-loss results in specific study populations. The STEP 1 trial reported an average body-weight reduction of 14.9% with branded injectable semaglutide 2.4 mg over 68 weeks. The SURMOUNT-5 trial found approximately 20.2% average body-weight loss with branded tirzepatide versus 13.7% with branded semaglutide over 72 weeks. These figures apply to FDA-approved branded medications in controlled clinical settings. They should not be interpreted as expected outcomes for compounded medications, Novi's program, or any individual patient. Individual results vary significantly.

View the current Novi offer (official Novi page)

The 2026 FDA Regulatory Picture: What Changed and What It Means Before You Commit

This is the section most review content either skips or buries in vague language. In 2026, that approach isn't just unhelpful - it's a disservice. The regulatory landscape for compounded GLP-1 programs has shifted meaningfully since early 2025, and anyone committing to a multi-month program deserves a plain-English summary of exactly where things stand.

The shortage justification is gone. The legal framework that made mass-market compounded GLP-1s widely available was built on FDA shortage designations for branded semaglutide and tirzepatide. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. With those designations removed, the broadest legal basis for "essentially a copy" compounding - under both 503A and 503B frameworks - no longer applies in the way it did during the shortage period.

The 503A patient-specific pathway still exists, but it's narrower than it appears. A 503A pharmacy can still compound a GLP-1 medication for a specific individual patient with a valid prescription from a licensed physician - but only when the compounded version is not "essentially a copy" of a commercially available drug. Since branded semaglutide and tirzepatide are now fully available, prescribers are expected to document that the compounded version serves a specific individualized medical need that the branded version cannot. Platforms operating in the 503A space after the shortage resolution are navigating genuinely unsettled legal ground. The publisher has not independently verified the exact pharmacy pathway or individualized-need documentation used for Novi prescriptions. Consumers should confirm pharmacy and compounding details directly with Novi before enrolling.

The 503B large-scale pathway is being formally restricted. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list. The FDA stated there is no longer a clinical need for outsourcing facilities to compound these agents. If finalized, this would prohibit 503B facilities from compounding these medications under any circumstances, even during a future shortage. A public comment period is open through June 29, 2026, via the federal docket. This is a proposed rule, not a final one - but the direction is unambiguous. Most telehealth companies, including Novi based on its program structure, use 503A patient-specific pharmacies rather than 503B outsourcing facilities, so this proposal does not directly affect their current operations. What it signals is the FDA's long-term intent.

Enforcement has been consistent throughout 2025 and 2026. The FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications in September 2025. In March 2026, it issued 30 additional warning letters targeting telehealth companies over advertising practices and compounding claims. Hims and Hers, previously one of the highest-volume platforms, faced significant legal and regulatory pressure around its compounded GLP-1 offerings in early 2026 and adjusted its strategy accordingly. As of the date of this publication, Novi has not been publicly named in FDA warning letters.

What this means for you: The honest risk is this - the FDA's consistent direction has been toward greater restriction of compounded GLP-1 access. A multi-month financial commitment to any compounded program is also a commitment to the regulatory uncertainty that comes with it. That's not a reason to automatically say no. It's information you should have before you decide.

What Novi Does Not Guarantee

Most guides skip this. We don't, because understanding these limits protects you - and because any program that would guarantee these things should actually raise your suspicion.

• Novi does not guarantee that every visitor will qualify for treatment.

• Novi does not guarantee that a prescription will be written. Per the Terms of Service, providers reserve the right to deny care for actual or potential misuse of services.

• Novi does not guarantee a specific amount of weight loss.

• Novi does not guarantee that promotional pricing will remain available at checkout.

• Novi does not guarantee insurance reimbursement.

• Novi does not guarantee that compounded GLP-1 availability or regulatory conditions will remain unchanged.

How the Novi GLP-1 Program Works

According to Novi's published materials, the enrollment process works in three stages.

Step 1: Online pre-approval quiz. A 3-minute intake form collects basic information about your health history and goals. Completing it doesn't mean you're enrolled, and it doesn't guarantee a prescription will be issued. It's a preliminary screening step, not a clinical decision.

Step 2: Clinician review. If your intake suggests you may be eligible, a U.S.-licensed clinician - one of the physicians or nurse practitioners the company names on its website - reviews your health profile and determines whether a prescription is appropriate. Per Novi's Terms of Service, there is no guarantee a prescription will be written.

Step 3: Prescription and delivery. If prescribed, according to the company's materials, medication ships with free 2-day delivery. Each monthly shipment includes a 4-week supply and the supplies needed for administration.

According to the company's website, the monthly price includes unlimited clinician access for check-ins, dose adjustments, and side-effect questions, plus coaching at no additional cost. Medication and supplies are bundled into the all-in price with no hidden fees. The Terms of Service note that a $20 per month independent physician consultation fee is included in the total - it's not charged separately.

Novi Cancellation Terms: The FAQ and the Terms of Service Say Two Different Things - Here's What to Confirm Before You Pay

This is the most searched question about Novi - and the area where two documents published on the same website give meaningfully different answers. This section isn't here to alarm you. It's here because it's your money, and understanding this before you enter your payment details costs you nothing.

What the FAQ says: Novi's FAQ describes the program as "month-to-month with no minimum commitments or long-term contracts, so cancellation is simple and flexible." It advises canceling before your next renewal date to avoid an additional charge.

What the Terms of Service says: The Terms of Service - published on the same website - describe a different structure. The relevant language states that subscription-based products and services "require a minimum 3-month commitment" because the company "incur[s] significant upfront cost." The Terms further state that "the first month's fee as well as the monthly fee for the following two months (for a total of three (3) consecutive months) is charged at the time of purchase and is non-refundable" unless a provider determines the treatment is medically inappropriate for you.

These statements appear inconsistent. Because the Terms of Service contain the more restrictive payment language, consumers should treat that document as the important one and confirm the applicable commitment, charge timing, cancellation deadline, and refund terms directly with Novi in writing before enrolling.

The Terms also include this language on disputes: customers who attempt to dispute charges to circumvent the 3-month commitment "will be sent to collections and/or have further legal action pursued."

The one step that protects you regardless: Email support@joinnovi.com before you pay. Ask specifically whether the 3-month upfront commitment applies to your enrollment under the offer you're considering. Get the answer in writing. This takes five minutes and eliminates the most preventable source of post-enrollment frustration. If the program is genuinely month-to-month for your enrollment, that confirmation is yours to keep. If the 3-month structure applies, you'll know exactly what you're committing to before you commit to it.

Novi Refund Policy: What's Covered and What Isn't

Per Novi's published refund policy, once a prescription has been dispensed or shipped, it cannot be returned or refunded. Canceling your subscription stops future shipments but does not generate a refund for medication that's already been processed and sent.

One documented exception exists in the Terms of Service: if a licensed clinician determines that the ordered services are not medically appropriate for you, the initial payment will be refunded to your original payment method. That's the only refund scenario explicitly covered in Novi's published materials.

If the medication causes side effects that make continuation difficult, that's a clinical conversation - not a refund pathway. The program includes unlimited clinician access for exactly this situation. GLP-1 nausea during early dose escalation is well-documented and often manageable by adjusting the escalation schedule. That clinical support, bundled into the monthly price, is a genuine differentiator. But the medication cost itself is non-refundable once shipped.

For support: support@joinnovi.com or care@joinnovi.com for order-related concerns.

View the current Novi offer (official Novi page)

Novi Pricing in Full Context: Where Things Stand in May 2026

Pricing is the most searched aspect of any GLP-1 telehealth program - and one of the areas where you need the most clarity before acting. Here's a complete picture of the current market based on verified, published data.

Novi's current pricing: According to offer-page source material reviewed for this guide, Novi advertised compounded semaglutide from $133 per month and compounded tirzepatide from $166 per month under a stated $200 promotional discount. Standard homepage, promotional landing page, and checkout pricing may each show different figures. Consumers should rely on the final checkout screen and written confirmation from Novi before enrolling - the promotional price is not guaranteed until confirmed at checkout.

What FDA-approved branded medications cost in 2026: Novo Nordisk reduced list pricing for injectable Wegovy; ongoing monthly fills run approximately $349 through NovoCare Pharmacy for most doses. The Wegovy pill (oral semaglutide, FDA-approved December 2025) carries cash pricing from $149 to $299 per month depending on dose, and is now available at more than 70,000 U.S. pharmacies. A CMS payment demonstration is expanding access for Medicare and Medicaid beneficiaries at reduced costs beginning mid-2026; this does not currently apply to most self-pay patients. Verify current branded pricing directly at NovoCare Pharmacy or LillyDirect.

How compounded competitors currently compare: The following examples are based on publicly available website claims reviewed at the time of publication and have not been independently verified by the publisher. Pricing, guarantee terms, refund eligibility, prescription availability, and fulfillment pathways may change without notice. Verify current terms directly with each provider before any enrollment decision.

• GobyMeds: Advertises compounded semaglutide from $99 per month, compounded tirzepatide from $133 per month. No consultation fee charged upfront - payment only after a prescription is approved and ships.

• Henry Meds: Compounded semaglutide starting around $149 per month in current market positioning.

• ShedRx: Advertises compounded semaglutide and tirzepatide with a stated 10% body weight loss guarantee within 9 months for eligible new users. A refund-backed guarantee structure is rare in this category; verify eligibility terms directly.

• MyStart Health: Advertises a 3-month plan from approximately $149 per month with a stated price-lock. Verify current terms and operational experience directly before enrolling.

Where Novi fits in this market: The relevant comparison depends on how much you expect to use the bundled support and how important factors like clinical access, coaching, and free shipping are relative to the starting price. At promotional pricing ($133/$166), Novi is among the more competitive entry points for compounded tirzepatide currently available. What Novi bundles into its monthly price - coaching, unlimited clinician access, supplies, and free 2-day shipping - provides additional value over programs that charge for those elements separately.

One additional note worth having: Hims and Hers has faced significant legal and regulatory pressure around compounded GLP-1 offerings, which has become part of the broader 2026 market context. That shift has reduced the number of well-capitalized platforms still actively operating in the compounded space - context worth holding onto for anyone evaluating long-term program continuity.

Semaglutide or Tirzepatide: How to Think About the Choice

Novi offers both options, and the question of which one makes sense is one of the most common things people search before enrolling. Here's what the clinical data on the FDA-approved branded versions shows - with the important note that compounded versions are legally and regulatorily distinct products, and individual results always vary.

Semaglutide works by targeting the GLP-1 receptor pathway. It has the longest clinical track record in weight management and is the most affordable option across Novi's lineup and most compounded telehealth programs.

Tirzepatide targets two receptor pathways - GLP-1 and GIP - which appear to amplify appetite suppression. The SURMOUNT-5 trial found approximately 20.2% average body-weight loss with branded tirzepatide versus 13.7% with branded semaglutide over 72 weeks in adults with obesity and without diabetes. Roughly 65% of branded tirzepatide participants in that trial achieved at least 15% body-weight loss, compared with 40% for branded semaglutide. These figures reflect FDA-approved drugs in controlled clinical settings - not Novi program expectations and not applicable to compounded versions.

On side effects, both classes most commonly produce gastrointestinal symptoms - nausea, vomiting, diarrhea, and constipation - primarily during dose escalation. These effects typically decrease as the body adjusts. There is no established clinical data confirming that compounded versions carry identical side-effect profiles to the branded drugs.

The clinician who evaluates you through Novi will make a prescription recommendation based on your actual health history. This section gives you context for that conversation - not a replacement for it.

Who May Want to Review Novi's Program Details

Based on verified information from Novi's published materials, here's an honest picture of who this program may be relevant for - and where additional caution makes sense before proceeding.

Novi may be relevant for adults who have already had a conversation with a licensed healthcare professional about GLP-1 therapy and have a general sense it may be appropriate for their situation. It may also suit people who are comfortable with a fully online program - intake, evaluation, clinical support, and delivery all handled remotely - and who are looking for a cash-pay, compounded GLP-1 option with clinical oversight included. Confirming the current cancellation terms with the support team before completing enrollment is a prerequisite regardless.

Who Should Speak With a Healthcare Professional Before Proceeding

Anyone with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, gallbladder disease, severe gastrointestinal conditions, pregnancy, breastfeeding, complex medication use, or other relevant medical concerns should discuss GLP-1 therapy with a qualified healthcare professional before considering enrollment in any program. This section is informational only and does not determine eligibility. A licensed provider must evaluate your individual health history before any prescription decision is made.

Is Novi Legitimate? Verification Points You Can Actually Check

People searching "is Novi legit" want checkable answers, not reassurance. Here are the specific verification points, based entirely on Novi's published materials.

LegitScript certification: Displayed on joinnovi.com with a clickable verification link. This credential is commonly required by major online advertising platforms and healthcare ecosystems as a verification signal for healthcare-related businesses. It confirms the platform has been reviewed against defined legal operation standards - though it doesn't guarantee clinical outcomes or future regulatory continuity.

Named licensed clinicians with disclosed credentials: Novi's website lists specific providers with their certifications - American Board of Emergency Medicine physicians, board-certified nurse practitioners, and a family nurse practitioner with over 25 years of clinical experience. Platforms that publish no clinician identity or credentials carry meaningfully higher risk than those that name their providers.

Published legal documentation: Terms of Service, Privacy Policy, Refund Policy, and Medical Consent are all live on the website. The presence of detailed legal terms - including the more restrictive payment language in the Terms of Service - is a transparency signal. Novi's documents disclose the 3-month commitment structure, the collections language, and the arbitration terms. Platforms that publish this level of documentation are operating more openly than those that share nothing.

Corporate registration: Novi International LLC is a registered legal entity with a mailing address of 30 N Gould St Ste R, Sheridan, Wyoming 82801.

Collectively, these indicators confirm Novi is not an anonymous web storefront. It is a registered, LegitScript-certified company operating with named licensed clinicians and published legal structure. That does not guarantee clinical outcomes, prescription approval, or regulatory continuity for compounded medications - but it answers the legitimacy question with verifiable facts.

View the current Novi offer (official Novi page)

Frequently Asked Questions About Novi GLP-1

Is Novi a legitimate telehealth platform?

Based on available verifiable indicators - LegitScript certification, named licensed clinicians with disclosed credentials, published Terms of Service and legal documentation, and corporate registration under Novi International LLC - the platform operates as a registered healthcare company, not an anonymous storefront. As with any prescription telehealth program, consulting a licensed healthcare professional and verifying current regulatory status independently before enrolling is recommended.

How much does Novi cost?

According to offer-page source material reviewed for this guide, Novi advertised promotional pricing of compounded semaglutide from $133 per month and compounded tirzepatide from $166 per month, reflecting a stated $200 discount. Other Novi pages and pricing structures may display different figures. The affiliate link in this guide routes to a promotional offer. Verify the exact price at your checkout screen before completing enrollment - that number is the only one that matters.

Is Novi month-to-month or does it charge three months upfront?

Novi's FAQ describes a month-to-month service with no long-term commitment. Novi's Terms of Service describe a 3-month minimum commitment with three months charged at purchase, described as non-refundable unless a provider determines treatment is medically inappropriate. These statements appear inconsistent. Email support@joinnovi.com before enrolling, ask which structure applies to your enrollment, and get the answer in writing. This is the single most important step between reading this guide and making a decision.

What is compounded semaglutide and how is it different from Ozempic^® or Wegovy^®?

Novi's materials describe its compounded semaglutide program as involving the same active ingredient associated with Ozempic^® and Wegovy^®. However, compounded semaglutide is not an FDA-approved finished drug product. It is not a generic equivalent of those branded medications. It has not been reviewed by the FDA for safety, effectiveness, or quality before marketing. It is legally distinct from FDA-approved drugs. Consult a licensed healthcare professional for a clinical comparison relevant to your individual health history.

Is compounded semaglutide or tirzepatide still legal in 2026?

The compounding landscape is genuinely unsettled in 2026. The FDA removed semaglutide from the drug shortage list in February 2025 and tirzepatide in December 2024. That removal eliminated the primary legal basis that had permitted "essentially a copy" compounding for both substances. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list; a public comment period runs through June 29, 2026. Patient-specific compounding under 503A by a licensed pharmacy may still be available where a prescriber documents individualized medical need, but this area involves actively evolving legal and regulatory interpretation. Consumers should verify current status and ask providers about their specific pharmacy pathway before enrolling.

Can I get a refund if the medication doesn't work or causes side effects?

Per Novi's published refund policy, once a prescription has been dispensed or shipped, it cannot be returned or refunded. The documented exception is if a licensed clinician determines that the treatment is not medically appropriate - in that case, per the Terms of Service, the initial payment is refunded. Side-effect management is handled through the program's unlimited clinician access, which is included in the monthly price. Canceling your subscription stops future shipments but does not generate a refund for medication already processed.

What states is Novi available in?

Per the Terms of Service, services are available only in U.S. states where Novi's services have been approved. No specific excluded-states list is published on the main website. Confirm availability in your state before completing the intake form.

Does Novi accept insurance?

Per the Terms of Service, all Novi services are cash-pay, generally not billed directly to insurance. The company states insurance may reimburse for branded options in some cases. Compounded medications are generally not covered by insurance as they are not FDA-approved finished products. Confirm coverage details with your insurer before enrolling.

How does tirzepatide compare to semaglutide for weight loss?

In clinical trials for FDA-approved branded versions, tirzepatide produced stronger average weight-loss outcomes in head-to-head data. The SURMOUNT-5 trial found approximately 20.2% average body-weight loss with branded tirzepatide versus 13.7% for branded semaglutide over 72 weeks. These figures reflect branded medications in controlled clinical settings and should not be interpreted as expected outcomes for compounded versions or any individual patient. Individual results vary significantly.

How fast will I see results on GLP-1 medication?

Clinical trial data for FDA-approved branded semaglutide showed meaningful weight changes beginning in weeks 4 through 12, with continued results accumulating over a 68-week period. Branded tirzepatide showed similar early response patterns with stronger results at 12 and 18 months in trial settings. These timelines reflect branded medications in controlled environments. Compounded versions are legally and regulatorily distinct products. Starting dose, escalation schedule, lifestyle factors, and individual health profile all affect the pace and degree of any weight change. Your prescribing clinician will manage dose progression based on your specific response.

How does Novi compare to GobyMeds, ShedRx, and other competitors?

Consumers comparing Novi with other cash-pay GLP-1 telehealth platforms should evaluate advertised starting price, whether medication is included, whether clinician access is bundled, whether coaching is included, shipping costs, cancellation terms, prescription eligibility requirements, pharmacy pathway, refund rules, and the quality of published legal disclosures. Some competitors advertise lower starting prices or different guarantee structures, but those claims should be verified directly with each provider before any enrollment decision. The relevant comparison depends on your priorities - starting cost, clinical support, financial guarantees, or all three.

What are the common side effects and how does Novi handle them?

GLP-1 receptor agonists, as a class, most commonly cause gastrointestinal effects - nausea, vomiting, diarrhea, and constipation - primarily during dose escalation. These effects typically decrease as the body adjusts. Novi's program includes unlimited clinician access for side-effect management and dose adjustment at no additional cost. Starting at a lower dose and escalating more gradually is the standard management approach. Any severe or persistent symptoms should be discussed with the prescribing clinician before continuing. Individual experiences and results vary significantly.

Novi GLP-1 Enrollment Checklist: 6 Things to Confirm Before You Pay

Before completing enrollment in any compounded GLP-1 telehealth program - including Novi - verify each of the following directly with the company, in writing, before entering your payment details.

1. Cancellation structure: Email support@joinnovi.com and ask whether the 3-month upfront commitment described in the Terms of Service applies to your specific enrollment. The FAQ says month-to-month. The Terms say three months charged at purchase, non-refundable. Get written confirmation of which applies to you before you pay.

2. Checkout price: Novi's promotional landing pages, standard homepage, and checkout screen may each show different numbers. The price on your checkout screen is the only figure that matters. Do not assume the price you saw in an ad or on a landing page is the price you'll be charged.

3. Pharmacy pathway: Ask Novi which compounding pharmacy fulfills prescriptions for your state and whether that pharmacy documents individualized medical need for each patient - the standard now expected under the post-shortage regulatory framework.

4. State availability: Per the Terms of Service, Novi's services are available only in approved states. No excluded-states list is published on the main website. Confirm your state is covered before completing the intake form.

5. Prescription eligibility: Completing the 3-minute quiz does not guarantee a prescription. A licensed clinician makes that determination based on your individual health profile. Per the Terms of Service, providers reserve the right to deny care.

6. Regulatory status: The FDA's public comment period on proposed restrictions for large-scale compounded GLP-1 medications closes June 29, 2026. Before committing to a multi-month program, understand what the current regulatory environment means for the availability and continuity of compounded GLP-1 access going forward.

Final Consumer Takeaway: What to Confirm Before Reviewing the Current Novi Offer

Here's the complete picture, assembled from everything verified in this guide.

Novi's published materials present a telehealth GLP-1 program with clinician review, prescription-based access for eligible patients, compounded semaglutide and tirzepatide options, unlimited clinical support, coaching, and promotional pricing on selected offer pages. The strongest reasons to look closely at Novi are its bundled all-in program structure, visible provider credentials, LegitScript certification, and competitive offer-page pricing. The strongest reasons to pause before enrolling are the cancellation document inconsistency and the genuinely unsettled regulatory environment for compounded GLP-1 medications in 2026.

The two steps that matter most before you spend a dollar:

First: Email support@joinnovi.com and confirm which cancellation structure applies to your specific enrollment - the FAQ's month-to-month description or the Terms of Service's 3-month upfront commitment. Get the answer in writing before you pay. This takes five minutes and eliminates the most preventable source of post-enrollment frustration.

Second: Be clear-eyed about the regulatory environment you're entering. Compounded GLP-1 medications are not FDA-approved finished products. The compounding landscape has changed materially in the last 12 months and continues to evolve. A multi-month commitment to any compounded program is also a commitment to that uncertainty.

With both of those things understood: for a patient who has done the clinical homework, confirmed the commitment terms directly with Novi, and is comparing cash-pay compounded options, Novi's all-in structure with coaching and unlimited clinician access may be relevant, especially if the promotional pricing, eligibility review, and pharmacy details are confirmed directly before enrollment.

This guide does not determine whether Novi is appropriate for any individual patient. That decision belongs to a licensed healthcare professional after reviewing your complete health history.

View the current Novi offer (official Novi page)

Contact Information

For enrollment questions, support, dose adjustments, or cancellation inquiries:

Company: Novi International LLC
Primary support email: support@joinnovi.com
Secondary email: care@joinnovi.com (order-related concerns)
Phone: 214-427-4553 (sourced from the SMS terms section of the website - confirm current support hours directly with the company)
Support availability: 7 days a week per the brand's published refund policy page
Mailing address: Novi International LLC, 30 N Gould St Ste R, Sheridan, WY 82801
Patient portal: join-novi.thimbleportal.ai/login
Support center: joinnovi.zendesk.com

Additional Novi GLP-1 Coverage

Readers researching Novi's compounded GLP-1 program may find the following previously published coverage useful. The piece below covers Novi's program structure, eligibility context, and the April 2026 regulatory environment from an awareness-stage perspective - complementary background for anyone working through the enrollment decision.

• Novi GLP-1 Program 2026: Compounded Semaglutide, Tirzepatide, Telehealth Eligibility, and Regulatory Context for Prospective Patients

Disclaimers

Affiliate Disclosure: This article contains affiliate links. If a purchase is made through links in this article, a commission may be earned at no additional cost to the reader. This compensation does not influence the accuracy, neutrality, or integrity of the information presented.

Advertorial Disclosure: This article is sponsored advertising content produced by an independent publisher in connection with a marketing arrangement. It is not independent editorial or medical advice. The publisher is responsible for the accuracy of the content as published.

Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified, licensed healthcare professional before starting, stopping, or changing any prescription treatment, including GLP-1 medications.

Prescription Eligibility Disclaimer: Completing an online quiz or intake form does not guarantee eligibility, approval, or a prescription. A licensed healthcare provider must determine whether treatment is appropriate based on your individual health information.

Compounded Medication Notice: Novi markets compounded semaglutide and compounded tirzepatide as prescription GLP-1 treatment options for eligible patients. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not generic equivalents of Ozempic^®, Wegovy^®, Mounjaro^®, or Zepbound^®. They have not been reviewed by the FDA for safety, effectiveness, or quality before marketing. They are legally distinct from FDA-approved branded medications. The FDA has received hundreds of adverse event reports associated with compounded semaglutide and compounded tirzepatide, and the FDA notes that adverse events are likely underreported. The FDA has also warned about dosing errors with compounded injectable semaglutide products, including some reports involving hospitalization. Patients should discuss risks, benefits, and potential side effects with a licensed healthcare professional before starting treatment. Ozempic^® and Wegovy^® are registered trademarks of Novo Nordisk A/S. Mounjaro^® and Zepbound^® are registered trademarks of Eli Lilly and Company. These brand names are referenced for nominative identification only and do not imply affiliation with or endorsement by those companies.

Regulatory Status Note: The regulatory environment for compounded GLP-1 medications is actively evolving. The FDA removed tirzepatide from the drug shortage list in December 2024 and semaglutide in February 2025, eliminating the primary legal basis for "essentially a copy" compounding of these substances. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list; a public comment period is open through June 29, 2026. Patient-specific compounding under 503A may continue where a prescriber documents individualized medical need, but this area involves actively evolving regulatory interpretation. Readers should verify current regulatory status independently before making enrollment decisions.

Results May Vary: Individual results from GLP-1 therapy vary significantly based on health profile, starting weight, adherence, dose, lifestyle factors, and other variables. Clinical trial data cited in this article refers to FDA-approved branded medications in controlled clinical settings. It does not represent expected outcomes for any compounded product, telehealth program, or individual patient. Individual experiences and results vary. Testimonials reflect brand-reported customer data and should not be interpreted as typical or expected outcomes.

Pricing Disclaimer: All pricing information reflects publicly available data from brand and competitor websites at time of publication. Pricing is subject to change without notice. Promotional pricing may differ from standard pricing. Verify the exact price you will be charged at checkout before completing any enrollment.

Publisher Responsibility Disclaimer: This content was produced by an independent publisher in connection with a marketing arrangement. The publisher is not affiliated with, sponsored by, or endorsed by Novi International LLC or any competitor platform referenced in this article.

Insurance Coverage Note: Novi services are cash-pay, generally not billed directly to insurance. Compounded medications are generally not covered by insurance as they are not FDA-approved finished products. Confirm coverage details with your insurer before making any enrollment decision.

SOURCE: Novi

Source: Novi